

INTRODUCTION	XVI
STUDY GOAL AND OBJECTIVES	XVI
REASONS FOR DOING THE STUDY	XVI
INTENDED AUDIENCE.....	XVII
SCOPE OF REPORT	XVII
METHODOLOGY	XVII
INFORMATION SOURCES.....	XVIII
AUTHOR'S CREDENTIALS	XVIII
RELATED BCC RESEARCH REPORTS.....	XVIII
BCC ONLINE SERVICES.....	XVIII
DISCLAIMER	XIX
EXECUTIVE SUMMARY	XX
<i>SUMMARY TABLE GLOBAL DRUGS OF ABUSE TESTING MARKET</i>	
<i>FORECAST, BY REGION, THROUGH 2014 (\$ MILLIONS)</i>	XXI
<i>SUMMARY FIGURE GLOBAL DRUGS OF ABUSE TESTING MARKET</i>	
<i>FORECAST BY REGION, 2006–2014 (\$ MILLIONS)</i>	XXI
OVERVIEW	1
DRUG ABUSE TESTING.....	1
INTRODUCTION.....	1
INTERNATIONAL DRUG TRAFFICKING AND ILLICIT	
DRUG USE TRENDS BY DRUG TYPE	1
<i>TABLE 1 NUMBER OF ILLICIT DRUG USERS GLOBALLY, 2003–2007</i>	
<i>(MILLIONS)</i>	2
<i>TABLE 2 GLOBAL DRUG SEIZURES BY COUNTRY, DRUG TYPE,</i>	
<i>AND QUANTITY, JANUARY–JUNE, 2007</i>	2
<i>TABLE 2 (CONTINUED)</i>	3
<i>TABLE 2 (CONTINUED)</i>	4
Amphetamine-Type Stimulants Market.....	5
Cannabis Market	5
Coca/Cocaine Market.....	6
<i>TABLE 3 GLOBAL ILLICIT CULTIVATION OF COCA/COCAINE, 2000–</i>	
<i>2007 (MT)</i>	6
Opium/Heroin Market	6
<i>TABLE 4 GLOBAL ILLICIT CULTIVATION OF OPIUM, 2000–2007</i>	
<i>(MT)</i>	7
INTERNATIONAL DRUG TRAFFICKING AND ILLICIT	
DRUG USE TRENDS BY GEOGRAPHIC REGION	7
Africa	7
Central America and Caribbean	8
North America	8
South America	9
East and Southeast Asia	10

South Asia.....	10
West Asia	10
Europe.....	11
Oceania.....	12
U.S. DRUGS OF ABUSE STATISTICS	12
National Household Survey on Drug Abuse: SAMHSA	
U.S.	12
Survey by Age and Drug Type.....	13
<i>TABLE 5 DRUG ABUSE STATISTICS IN THE U.S. BY DRUG TYPE (12</i>	
<i>YRS AND OLDER), 2005 AND 2006 (THOUSANDS).....</i>	<i>13</i>
Survey by Age	13
<i>TABLE 6 ILLICIT DRUG USE IN LIFETIME AMONG PERSONS 12</i>	
<i>YRS AND OLDER IN THE U.S. BY AGE, 2005 AND 2006</i>	
<i>(THOUSANDS).....</i>	<i>14</i>
Survey by Gender and Drug Type.....	15
<i>TABLE 7 TYPES OF ILLICIT DRUG USE IN LIFETIME AMONG</i>	
<i>PERSONS 12 YRS AND OLDER IN THE U.S. BY GENDER, 2005</i>	
<i>AND 2006 (THOUSANDS).....</i>	<i>15</i>
Survey by Race and Ethnicity	15
<i>TABLE 8 ILLICIT DRUG USE IN LIFETIME AMONG PERSONS 12</i>	
<i>YRS AND OLDER IN THE U.S. BY RACE AND ETHNICITY, 2005</i>	
<i>AND 2006 (THOUSANDS).....</i>	<i>15</i>
<i>TABLE 8 (CONTINUED).....</i>	<i>16</i>
Survey by Geographic Divisions and County Types.....	16
<i>TABLE 9 ILLICIT DRUG USE IN LIFETIME AMONG PERSONS AGED</i>	
<i>12 OR OLDER IN THE U.S. BY GEOGRAPHIC DIVISIONS AND</i>	
<i>COUNTY TYPES 2005 AND 2006 (THOUSANDS).....</i>	<i>16</i>
Survey by Education and Current Employment	
Status	17
<i>TABLE 10 ILLICIT DRUG USE IN LIFETIME AMONG PERSONS</i>	
<i>AGED 12 OR OLDER BY EDUCATION AND EMPLOYMENT, 2005</i>	
<i>AND 2006 (THOUSANDS).....</i>	<i>17</i>
<i>TABLE 11 U.S. WORKFORCE ANNUAL DRUGS OF ABUSE</i>	
<i>POSITIVITY RATE, 1990–2003 (%).....</i>	<i>17</i>
DRUGS OF ABUSE STATISTICS, AUSTRALIA.....	18
<i>TABLE 12 PROPORTION OF AUSTRALIAN POPULATION USING</i>	
<i>ILLICIT DRUGS AGED 14 YEARS AND OVER BY DRUG TYPE,</i>	
<i>1995-2007 (%).....</i>	<i>18</i>
DRUGS OF ABUSE STATISTICS, CENTRAL ASIA.....	18
<i>TABLE 13 DRUG ABUSE STATISTICS IN CENTRAL ASIA, 2006.....</i>	<i>18</i>
DRUGS OF ABUSE TESTING PRACTICES.....	19
SINGLE VS MULTI-PARAMETER TEST	19
DOA SCREENING.....	19
CONFIRMATION TESTING	20

URINE TESTS	21
OTHER TESTING METHODS	21
BLOOD TESTING.....	22
ORAL FLUID TESTING.....	22
SALIVA TESTING	22
SWEAT TESTING.....	22
HAIR TESTING	23
TESTING LOCATIONS.....	23
LABORATORY-BASED DAT	23
Criminal Justice	24
Police	25
Prisons.....	25
Probation.....	25
Workplace Screening	25
Military	26
Customs and Excise.....	26
Education	26
POINT OF CARE DATS	27
<i>TABLE 14 ADVANTAGES AND DISADVANTAGES OF POINT OF</i>	
<i>CARE TESTING</i>	<i>27</i>
ONSITE TESTING VS LABORATORY TESTING	28
<i>TABLE 15 MAJOR ADVANTAGES AND DISADVANTAGES OF</i>	
<i>ONSITE TESTING.....</i>	<i>28</i>
SAMPLE TYPES FOR LABORATORY TESTING.....	28
URINE TESTING	28
HAIR TESTING	29
SALIVA/ORAL FLUID TESTING.....	29
BLOOD TESTING.....	30
SWEAT TESTING.....	30
EYE REFLEX.....	30
DETECTION PERIOD	31
<i>TABLE 16 DETECTION PERIODS FOR VARIOUS TYPES OF DRUG</i>	
<i>TESTING</i>	<i>31</i>
FOOLING A DRUG TEST.....	31
FOOLING URINE TESTING	32
<i>TABLE 17 COMMON PARAMETERS TESTED FOR URINE SPECIMEN</i>	
<i>VALIDITY</i>	<i>33</i>
<i>TABLE 18 SOME OF THE COMMERCIAL/COMMON ADULTERANTS</i>	
<i>USED IN FOOLING URINE TESTS AND THEIR EFFECTS.....</i>	<i>33</i>
<i>TABLE 18 (CONTINUED).....</i>	<i>34</i>
FOOLING HAIR TESTING	35
FOOLING SALIVA TESTING.....	35
SAMPLE VALIDITY TESTS.....	35
<i>TABLE 19 URINE SAMPLE VALIDITY TEST METHODS</i>	<i>35</i>

<i>TABLE 19 (CONTINUED)</i>	36
FALSE POSITIVES AND FALSE NEGATIVES.....	37
FALSE POSITIVES	37
<i>TABLE 20 CROSS REACTANTS THAT CAN LEAD TO FALSE</i>	
<i>POSITIVES IN DOA TESTING</i>	37
<i>TABLE 20 (CONTINUED)</i>	38
FALSE NEGATIVES	38
TESTING TECHNOLOGIES	38
IMMUNOASSAYS	39
ENZYME IMMUNOASSAY (EIA).....	39
ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA).....	39
ENZYME MULTIPLIED IMMUNOASSAY TECHNOLOGY.....	40
FLUORESCENCE POLARIZATION IMMUNOASSAY (FPIA)	40
RADIOIMMUNOASSAY (RIA).....	41
CHROMATOGRAPHY.....	41
Gas Chromatography (GC).....	41
High Performance Liquid Chromatography (HPLC)	41
Thin-Layer Chromatography (TLC)	42
Mass Spectrometry (MS)	42
Capillary Electrophoresis (CE)	42
Hyphenated MS/Chromatography.....	43
Gas-Chromatography-Mass Spectrometry	43
EYE REFLEX MEASUREMENTS.....	43
Eye Reflex Measurements (Continued)	44
GOVERNMENT REGULATIONS: DRUG TRAFFICKING AND DRUG	
ABUSE TESTING	45
NORTH AMERICA	45
NATIONAL LEGISLATION AND POLICY	45
Canada	45
Drug Free Workplace.....	45
Mexico	46
The United States.....	46
Drug-Free Workplace.....	47
<i>TABLE 21 U.S. DRUG TESTING LEGISLATIONS BY STATE, 2008</i>	48
<i>TABLE 21 (CONTINUED)</i>	49
<i>TABLE 21 (CONTINUED)</i>	50
<i>TABLE 21 (CONTINUED)</i>	51
<i>TABLE 21 (CONTINUED)</i>	52
U.S. Department of Transportation	53
Drug Testing in the Military	53
SOUTH AMERICA	53
NATIONAL LEGISLATION AND POLICY	53
Bolivia	54
Brazil.....	54

Drug-Free Workplace.....	55
Colombia	55
Ecuador	55
Guyana	56
Paraguay	56
Peru	56
CENTRAL AMERICA AND THE CARIBBEAN	57
NATIONAL LEGISLATION AND POLICY	57
Costa Rica	57
Cuba	57
El Salvador.....	57
Guatemala.....	58
Haiti	58
Jamaica	58
Nicaragua.....	58
Panama	58
Tegucigalpa	59
The Bahamas	59
The Netherlands Antilles	59
Trinidad and Tobago	59
EUROPE.....	59
NATIONAL LEGISLATION AND POLICY	59
Bosnia and Herzegovina.....	59
Denmark	60
France	60
Germany.....	60
Italy	61
Latvia	61
Norway	61
Romania	61
Sweden	62
Switzerland.....	62
The Netherlands.....	62
The United Kingdom	63
DRUG-FREE WORKPLACE POLICY AND LEGISLATION BY EUROPEAN COUNTRY	64
<i>TABLE 22 DRUG-TESTING LEGISLATION BY EUROPEAN COUNTRY, 2008.....</i>	<i>64</i>
<i>TABLE 22 (CONTINUED).....</i>	<i>65</i>
<i>TABLE 22 (CONTINUED).....</i>	<i>66</i>
<i>TABLE 22 (CONTINUED).....</i>	<i>67</i>
ASIA PACIFIC	68
NATIONAL LEGISLATION AND POLICY	68
Australia	68

Bangladesh	68
Bhutan	69
Cambodia	69
Hong Kong	69
India	70
The NDPS (Regulation of Controlled Substances) Order, 1993	70
Japan.....	71
Maldives.....	71
Myanmar.....	72
Nepal.....	72
New Zealand	73
Singapore	73
South Korea	73
Sri Lanka	74
Taiwan	75
Thailand.....	75
Vietnam.....	76

GLOBAL DRUGS OF ABUSE TESTING MARKET BY SAMPLE MATRIX.....	77
DRUGS OF ABUSE TESTING SALES	77
<i>TABLE 23 GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY SAMPLE MATRIX, THROUGH 2014 (\$ MILLIONS)</i>	77
<i>FIGURE 1 GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY SAMPLE MATRIX, 2006–2014 (\$ MILLIONS)</i>	78
GLOBAL SALES OF DRUGS OF ABUSE TESTING BY URINE	78
<i>TABLE 24 GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY URINE, THROUGH 2014 (\$ MILLIONS/%)</i>	79
<i>FIGURE 2 GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY URINE, 2006–2014 (\$ MILLIONS)</i>	79
<i>TABLE 25 GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY URINE: LABORATORY BASED VERSUS ONSITE, THROUGH 2014 (\$ MILLIONS)</i>	80
<i>FIGURE 3 GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY URINE: LABORATORY BASED VERSUS ONSITE, 2007 (%)</i>	80
GLOBAL SALES OF DRUGS OF ABUSE TESTING BY BLOOD	81
<i>TABLE 26 GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY BLOOD, THROUGH 2014 (\$ MILLIONS/%)</i>	81
<i>FIGURE 4 GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY BLOOD, 2006–2014 (\$ MILLIONS)</i>	81
GLOBAL SALES OF DRUGS OF ABUSE TESTING BY ORAL FLUID	82
<i>TABLE 27 GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY ORAL FLUID, THROUGH 2014 (\$ MILLIONS/%)</i>	82

<i>FIGURE 5 GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY ORAL FLUID, 2006–2014 (\$ MILLIONS)</i>	82
<i>TABLE 28 GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY ORAL FLUID: LABORATORY BASED VERSUS ONSITE, THROUGH 2014 (\$ MILLIONS)</i>	83
<i>FIGURE 6 GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY ORAL: LABORATORY BASED VERSUS ONSITE, 2006 AND 2014 (%)</i>	83
<i>GLOBAL SALES OF DRUGS OF ABUSE TESTING BY HAIR</i>	84
<i>TABLE 29 GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY HAIR, THROUGH 2014 (\$ MILLIONS/%)</i>	84
<i>FIGURE 7 GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY HAIR, 2006–2014 (\$ MILLIONS)</i>	84
<i>GLOBAL SALES OF DRUGS OF ABUSE TESTING BY SWEAT</i>	85
<i>TABLE 30 GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY SWEAT, THROUGH 2014 (\$ MILLIONS/%)</i>	85
<i>FIGURE 8 GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY SWEAT, 2006–2014 (\$ MILLIONS)</i>	85
<i>GLOBAL SALES OF DRUGS OF ABUSE TESTING BY OTHER SAMPLE MATRICES</i>	86
<i>TABLE 31 GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY OTHER SAMPLE MATRICES, THROUGH 2014 (\$ MILLIONS/%)</i>	86
<i>FIGURE 9 GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY OTHER SAMPLE MATRICES, 2006–2014 (\$ MILLIONS)</i>	86
WORLDWIDE INDUSTRY STRUCTURE	87
REGIONAL ANALYSIS	87
<i>FIGURE 10 DRUGS OF ABUSE TESTING MARKETS BY GEOGRAPHIC REGIONS, 2007 (%)</i>	87
<i>FIGURE 10 (CONTINUED)</i>	88
TOTAL DOA TESTING AND DRUG MONITORING MARKETS AND FORECASTS	88
<i>TABLE 32 GLOBAL DRUGS OF ABUSE TESTING MARKET FORECAST, THROUGH 2014 (\$ MILLIONS/%)</i>	88
<i>TABLE 33 DRUGS OF ABUSE TESTING BY LABORATORY, ONSITE, AND HOME TESTING MARKET FORECAST, 2006–2014 (\$ MILLIONS/%)</i>	88
GROWTH TRENDS—LABORATORY BASED AND ONSITE DOA TESTING MARKETS	89
LABORATORY-BASED DOA TESTING MARKETS AND FORECASTS	89
<i>TABLE 34 DRUGS OF ABUSE TESTING MARKET FORECAST FOR LABORATORY-BASED TESTING, 2006–2014 (\$ MILLIONS/%)</i>	89

ONSITE DOA TESTING MARKETS AND FORECASTS	89
<i>TABLE 35 DRUGS OF ABUSE TESTING MARKET FORECAST FOR</i>	
<i>ONSITE TESTING, THROUGH 2014 (\$ MILLIONS/%)</i>	89
COMPETITIVE ANALYSIS	89
<i>TABLE 36 MOST NOTABLE MERGERS AND ACQUISITIONS IN THE</i>	
<i>DOA TESTING MARKETS, 2000–2007</i>	90
Key Market Players in the DOA Testing Markets and	
Their Products	90
<i>TABLE 37 MAJOR COMPANIES AND THEIR PRODUCTS IN THE</i>	
<i>DOA TESTING MARKET</i>	91
LABORATORY-BASED DOA TESTING MARKET SEGMENT	92
<i>TABLE 38 COMPANIES OFFERING LABORATORY-BASED DOA</i>	
<i>TESTING PRODUCTS</i>	92
<i>TABLE 38 (CONTINUED)</i>	93
ONSITE TESTING MARKET SEGMENT FOR DOA.....	94
<i>TABLE 39 MAIN ONSITE DOA TESTING MARKET PLAYERS AND</i>	
<i>THEIR PRODUCTS</i>	94
<i>TABLE 39 (CONTINUED)</i>	95
COMMON DRUGS OF ABUSE AND MOST POPULAR	
DEVICES USED FOR TESTING THEM	95
<i>TABLE 40 COMMON DOA AND POPULAR URINE DRUG SCREENING</i>	
<i>PRODUCTS</i>	95
<i>TABLE 40 (CONTINUED)</i>	96
COMPANIES IN THE ORAL FLUID, HAIR, AND SWEAT	
TESTING SEGMENTS FOR DOA.....	96
<i>TABLE 41 KEY MARKET PLAYERS OFFERING DOA TESTING</i>	
<i>PRODUCTS ON ORAL FLUID, HAIR, AND SWEAT SAMPLE</i>	
<i>MATRICES</i>	97
COMPANY PROFILES	97
ABBOTT LABORATORIES	97
Abbott Hematology—Diagnostics Division.....	97
ACON LABORATORIES, INC.	98
AMERICAN BIO MEDICA CORP. (ABMC)	99
AVITAR, INC.....	99
BECKMAN COULTER	100
BIO-RAD LABORATORIES, INC	101
CONCATENO, PLC	101
F. HOFFMANN-LA ROCHE, LTD.....	102
INVERNESS MEDICAL INNOVATIONS, INC.....	102
MEDTOX SCIENTIFIC, INC.	103
MICROGENICS	104
NANOGEN, INC.	104
OLYMPUS DIAGNOSTICS SYSTEMS	105
ORASURE TECHNOLOGIES, INC.....	105

SIEMENS MEDICAL SOLUTIONS USA, INC.....	106
VARIAN, INC.....	106
Varian, Inc. (Continued).....	107
PATENT ANALYSIS.....	108
<i>TABLE 42 U.S. DRUGS OF ABUSE TESTING PATENTS BY</i>	
<i>ASSIGNEE, 1978–2007</i>	108
<i>TABLE 42 (CONTINUED)</i>	109
<i>TABLE 42 (CONTINUED)</i>	110
<i>TABLE 42 (CONTINUED)</i>	111
<i>TABLE 42 (CONTINUED)</i>	112
APPENDIX	113
<i>TABLE 43 GLOSSARY OF COMMON TERMS</i>	113
<i>TABLE 43 (CONTINUED)</i>	114
<i>TABLE 43 (CONTINUED)</i>	115
<i>TABLE 43 (CONTINUED)</i>	116
<i>TABLE 43 (CONTINUED)</i>	117
<i>TABLE 44 GLOSSARY OF SCIENTIFIC ABBREVIATIONS</i>	118
<i>TABLE 45 ASSOCIATIONS</i>	118